Generic
Trilaciclib
1 brands available in the market
At a glance
Trilaciclib is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
Description
Trilaciclib is a transient inhibitor of CDK 4 and 6. Hematopoietic stem and progenitor cells (HSPCs) in the bone marrow give rise to circulating neutrophils, RBCs, and platelets. HSPC proliferation is dependent on CDK4/6 activity.
Indications
- Decrease incidence of chemotherapy-induced myelosuppression (ES-SCLC)
Therapeutic class
Transient inhibitor
Pharmacological class
CDK 4/6 Inhibitor
Pharmacology
Trilaciclib is a transient inhibitor of CDK 4 and 6. HSPC proliferation is dependent on CDK4/6 activity. Trilaciclib causes transient G1 arrest of hematopoietic stem cells, contributing to its myeloprotective effect.
Mechanism of action
Inhibits CDK4/6, causing transient G1 arrest of HSPCs, providing myeloprotection.
Dosage
Adult Dose (IV):
- 240 mg/m² per dose as a 30-minute IV infusion completed within 4 hours prior to chemotherapy
- Interval between doses on sequential days should not be greater than 28 hours
- Missed dose: discontinue chemotherapy on the day the Trilaciclib dose was missed; consider resuming both on the next scheduled day
- Discontinuation: wait 96 hours from last dose before resumption of chemotherapy only
Administration
- Administered by a healthcare professional as IV infusion
- Use 0.2 or 0.22 micron in-line filter
- Do not use PTFE in-line filter
- Do not co-administer other drugs through the same infusion line
- Flush line/cannula with at least 20 mL sterile 0.9% Sodium Chloride or 5% Dextrose after infusion
Missed dose
If the Trilaciclib dose is missed, discontinue chemotherapy on the day the Trilaciclib dose was missed. Consider resuming both Trilaciclib and chemotherapy on the next scheduled day for chemotherapy.
Side effects
Common Side Effects:
- Injection-site reactions (phlebitis, thrombophlebitis)
- Acute drug hypersensitivity reactions
- ILD/pneumonitis
Precautions & warnings
- Monitor for injection-site reactions
- Monitor for acute hypersensitivity reactions
- Monitor for pulmonary symptoms of ILD/pneumonitis (cough, dyspnea, hypoxia)
- May cause fetal harm; use effective contraception
Contraindications
- History of serious hypersensitivity reactions to Trilaciclib (including anaphylaxis)
Drug interactions
- OCT2, MATE1, MATE-2K inhibitors: may increase concentration of substrates (dofetilide, dalfampridine, cisplatin) in kidney
Food interactions
Food interactions are not significant.
Use in pregnancy
Use in Pregnancy: Can cause fetal harm; advise pregnant women of potential risk.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Use in lactation
Use in Lactation: Unknown if excreted in human milk; do not breastfeed while taking and for at least 3 weeks after last dose.
Pediatric use
Safety and efficacy not established in pediatric patients
Geriatric use
No overall differences in safety or effectiveness in elderly
Renal / hepatic impairment
Renal Impairment: No dose adjustment necessary
Hepatic Impairment: No dose adjustment necessary
Overdose effects
Symptoms: Drowsiness, disorientation, extrapyramidal reactions.
Treatment: Anticholinergic, antiparkinsonism, or antihistamine drugs; supportive.
Storage conditions
Store below 30°C, away from light and moisture; keep out of reach of children.